An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“
/in IOZK Veröffentlichungen /von IOZKBeitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
/in Externe Meldungen, IOZK In der Presse /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives